Sudden cardiac death and implantable cardioverter defibrillators: Two modern epidemics?

Europace

Volumn 14, Issue 6, 2012, Pages 787-794

  Katritsis, Demosthenes G ^a,b   Josephson, Mark E ^c  

^a Athens Euroclinic   (Greece)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Arrhythmic death; Implantable cardioverter defibrillators; Primary prevention; Secondary prevention; Sudden cardiac death

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; EPIDEMIC; HEART ARREST; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; ISCHEMIC CARDIOMYOPATHY; LIFE EXPECTANCY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SURVIVAL;

ARRHYTHMIAS, CARDIAC; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EPIDEMICS; HUMANS; RISK FACTORS;

EID: 84861582228     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eus001     Document Type: Review

References (71)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al.; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012;125: e2-e220.
2. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/ AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:746-837.
3. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997;30:1500-5.
4. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80: 1675-80.
5. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-9.
6. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: structure, function, and time-dependence of risk. Circulation 1992;85(Suppl I):I-1-10.
7. Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out ofhospital ventricular fibrillation, 1980-2000. JAMA 2002;288:3008-13.
8. Nichol G, Thomas E, Callaway CW, Hedges J, Powell JL, Aufderheide TP, et al. Resuscitation Outcomes Consortium Investigators. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA 2008;300:1423-31.
9. Weisfeldt ML, Everson-Stewart S, Sitlani C, Rea T, Aufderheide TP, Atkins DL, et al. Resuscitation Outcomes Consortium Investigators. Ventricular tachyarrhythmias after cardiac arrest in public versus at home. N Engl J Med 2011;364: 313-21.
10. Adabag AS, Therneau TM, Gersh BJ, Weston SA, Roger VL. Sudden death after myocardial infarction. JAMA 2008;300:2022-9.
11. Myerburg RJ, Kessler KM, Mallon SM, Cox MM, deMarchena E, Interian A Jr, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med 1992;326:1451-5.
12. Olshausen KV, Stienen U, Schwartz F, Kubler W, Meyer J. Long-term prognostic significance of ventricular arrhythmias in idiopathic dilated-cardiomyopathy. Am J Cardiol 1988;61:146-51.
13. Berdowski J, ten Haaf M, Tijssen JG, Chapman FW, Koster RW. Time in recurrent ventricular fibrillation and survival after out-of-hospital cardiac arrest. Circulation 2010;122:1101-8.
14. Bunch TJ, White RD, Gersh BJ, Meverden RA, Hodge DO, Ballman KV, et al. Longterm outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med 2003;348:2626-33.
15. Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-203.
16. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-83.
17. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008;52:1111-21.
18. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.
19. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748-54.
20. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-8.
21. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted Defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. New Engl J Med 1996;335:1933-40.
22. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. Randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. New Engl J Med 1999;341:1882-90.
23. Fogoros RN. Evidence-based medicine and the implantable defibrillator. Curr Cardiol Rep 1999;1:135-41.
24. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. New Engl J Med 1997; 337:1569-75.
25. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New Engl J Med 2002;346:877-83.
26. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004;109:1082-4.
27. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. DINAMIT Investigators. Prophylactic use of an implantable cardioverterdefibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8.
28. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009;361:1427-36.
29. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, et al. Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352:2581-8.
30. Bardy GH, Lee KL, Mark DB, Poole JE, Toff WD, Tonkin AM, et al. HAT Investigators. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med 2008;358:1793-804.
31. Sharma PP, Greenlee RT, Anderson KP, Chyou PH, Osorio HJ, Smith PN, et al. Prevalence and mortality of patients with myocardial infarction and reduced left ventricular ejection fraction in a defined community: relation to the second multicenter automatic defibrillator implantation trial. J Interv Card Electrophysiol 2007; 19:157-64.
32. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New Engl J Med 2005; 352:225-37.
33. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
34. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. AMIOVIRT Investigators. Amiodarone versus implantable cardioverter defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003;41:1707-12.
35. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. New Engl J Med 2004;350:2151-8.
36. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004;292:2874-9.
37. Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta analysis. Europace 2010;12:1564-70.
38. Fishman GI, Chugh SS, Dimarco JP, Albert CM, Anderson ME, Bonow RO, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010;122:2335-48.
39. Stecker EC, Vickers C,Waltz J, Socoteanu C, John BT, Mariani R, et al. Populationbased analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006;47:1161-6.
40. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, et al. MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 2007;50:1150-7.
41. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003;42:736-42.
42. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51: 288-96.
43. Kaltman JR, Thompson PD, Lantos J, Berul CI, Botkin J, Cohen JT, et al. Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. Circulation 2011;123:1911-8.
44. Modi S, Krahn AD. Sudden cardiac arrest without overt heart disease. Circulation 2011;123:2994-3008.
45. Tan HL, Hofman N, van Langen IM, van der Wal AC, Wilde AA. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 2005;112:207-13.
46. Chugh SS, Senashova O, Watts A, Tran PT, Zhou Z, Gong Q, et al. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol 2004;43: 1625-9.
47. Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R, Bhuripanyo K, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003;107:2221-6.
48. Krahn AD, Connolly SJ, Roberts RS, Gent M. Diminishing proportional risk of Sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004;147:837-40.
49. Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, Santarelli P, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverterdefibrillators. Ann Intern Med 2010;153:592-9. Erratum in: Ann Intern Med. 2011;154:780.
50. Healey JS, Hallstrom AP, Kuck KH, Nair G, Schron EP, Roberts RS, et al. Role of the implantable defibrillator among elderly patients with a history of lifethreatening ventricular arrhythmias. Eur Heart J 2007;28:1746-9.
51. Epstein AE, Kay GN, Plumb VJ, McElderry HT, Doppalapudi H, Yamada T, et al. ACT Investigators. Implantable cardioverter-defibrillator. Prescription in the elderly. Heart Rhythm 2009;6:1136-43.
52. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
53. Henyan NN, White CM, Gillespie EL, Smith K, Coleman CI, Kluger J. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. J Intern Med 2006; 260:467-73.
54. Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, et al. Effectiveness of implantable cardioverter defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:1500-6.
55. Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm 2010;7:876-82.
56. Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998;136:205-12.
57. Lampert R, McPherson CA, Clancy JF, Caulin-Glaser TL, Rosenfeld LE, Batsford WP. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators. J Am Coll Cardiol 2004;43:2293-9.
58. Camm AJ, Klein H, Nissam S. The cost of implantable defibrillators: perceptions and reality. Eur Heart J 2007;28:392-7.
59. Hlatky MA, Mark DB. The high cost of implantable defibrillators. Eur Heart J 2007; 28:388-91.
60. Mark DB, Hlatky M.A. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 2002;106:516-20.
61. Mark DB, Hlatky M.A. Medical economics and the assessment of value in cardiovascular medicine: Part II. Circulation 2002;106:626-30.
62. Heidbuchel H. The cost of implantable defibrillators: how the perception of reality depends on perspective. Eur Heart J 2007;28:386-7.
63. Leyva F, Fernandez Lozano I, Morgan J Cardioverter-defibrillators: a cost or an investment? Europace 2011 13(Suppl 2) ii25-31
64. Larsen G, Hallstrom A, McAnulty J, Larsen G, Hallstrom A, McAnulty J, et al. AVID Investigators. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 2002;105:2049-57.
65. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Costeffectiveness of the implantable cardioverter defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001;103:1416-21.
66. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter defibrillators. New Engl J Med 2005;353:1471-80.
67. Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, et al. The cost effectiveness of implantable cardioverter defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47:2310-8.
68. Cowie MR, Marshall D, Drummond M, Ferko N, Maschio M, Ekman M, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace 2009;11:716-26.
69. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005;111:2906-12.
70. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16.
71. Katritsis DG, Ioannidis JP. PCI for stable coronary disease. N Engl J Med 2007;357: 414-5.